Heren Health(300550)2023-04-26 16:00Financial Performance - The company's revenue for Q1 2023 was ¥99,613,612.14, representing a 3.24% increase compared to ¥96,487,443.02 in the same period last year[5] - Net profit attributable to shareholders decreased by 82.96% to ¥956,609.42 from ¥5,612,548.39 year-on-year[5] - The net profit after deducting non-recurring gains and losses fell by 91.65% to ¥360,243.68 from ¥4,316,583.13 in the previous year[5] - Basic earnings per share decreased by 83.18% to ¥0.0036 from ¥0.0214 year-on-year[5] - Net profit for the current period was ¥1,040,421.08, a decrease of 79.2% from ¥5,000,802.37 in the previous period[22] - Total comprehensive income for the current period was ¥1,040,421.08, down 79.2% from ¥5,000,802.37 in the previous period[22] Cash Flow and Liquidity - Operating cash flow improved by 31.58%, with a net cash flow of -¥67,272,102.46 compared to -¥98,320,707.37 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥67,272,102.46, an improvement from the previous period's outflow of ¥98,320,707.37[25] - Cash and cash equivalents at the end of the period increased to ¥504,860,115.00 from ¥279,765,828.19, marking a significant recovery[25] - Investment activities generated a net cash inflow of ¥39,827,347.81, a turnaround from the previous period's outflow of ¥51,327,019.96[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,445,814,829.99, a 1.30% increase from ¥1,427,259,420.83 at the end of the previous year[5] - The company's total liabilities increased to CNY 403,224,944.07 from CNY 385,709,955.99 at the beginning of the year, reflecting a growth of approximately 4.0%[19] - The total current liabilities increased to CNY 401,102,090.82 from CNY 383,567,239.95, reflecting a rise of approximately 4.5%[19] - The cash and cash equivalents at the end of the first quarter were CNY 510,708,292.17, slightly up from CNY 506,315,013.83 at the beginning of the year[17] - Accounts receivable rose to CNY 202,807,517.25 from CNY 190,972,044.67, indicating an increase of about 6.9%[17] - Inventory levels increased significantly to CNY 70,352,716.27 from CNY 53,074,448.49, representing a growth of approximately 32.5%[18] - The company's contract assets grew to CNY 331,264,408.27 from CNY 301,913,862.80, marking an increase of about 9.7%[18] - The total equity attributable to the parent company was CNY 1,041,111,041.06, up from CNY 1,040,154,431.64 at the beginning of the year[19] Shareholder Information - The company reported a total of 8,270 ordinary shareholders at the end of the reporting period[10] - The largest shareholder, Hangzhou Panyuan Investment Co., Ltd., holds 44.32% of the shares, amounting to 116,454,980 shares[10] Operational Costs and Expenses - Total operating costs increased significantly to ¥106,164,933.55, up 15.8% from ¥91,655,643.72 in the previous period[20] - Research and development expenses decreased slightly to ¥14,566,041.41 from ¥15,013,335.86, reflecting a reduction of 3.0%[21] - The company incurred financial expenses of -¥2,140,790.12, compared to -¥350,426.97 in the previous period, indicating a significant increase in financial costs[21] Other Information - The company experienced a significant decline in profit margins due to increased human resource investments and adverse industry conditions[9] - The first quarter report of Zhejiang Heren Technology Co., Ltd. is unaudited[26] - The company plans to transfer 26,273,850 shares, representing 10.00% of the total share capital, to Xiamen Silicon Valley Shaohua No. 1 Investment Partnership[15] - A transfer of 49,920,315 shares, accounting for 19.00% of the total share capital, to Tongce Medical has been completed[16]